Please note the following updates that occurred after the simulcast:
“Mechanism of Action of GLP-1 Receptor Agonists” slide: GLP-1 receptor agonists may increase cardiac output. The slide incorrectly lists a decrease in cardiac output as a mechanism of action of GLP-1 receptor agonists.
“Currently Available GLP-1 RAs” slide: The oral formulation of semaglutide was added to the slide after FDA approval. Oral semaglutide (Rybelsus®) is dosed once daily by mouth and is available in 3 mg, 7 mg, and 14 mg tablets.
“Available GLP-1 Receptor Agonists” slide: The oral formulation of semaglutide was added to the slide after FDA approval. For oral semaglutide, start with 3 mg PO once daily for 30 days, then increase to 7 mg daily. The dose may be increased to 14 mg if needed after 30 days on the 7 mg dose. Take oral semaglutide at least 30 minutes before the first food, beverage, or other oral medication of the day with no more than 4 oz. of water.
A Virtual Reality Learning Experience: Integrating GLP-1 Receptor Agonists into T2DM Practice—Why, When, and How
Dhiren Patel, PharmD, CDE, BC-ADM, BCACP
Clinical Pharmacy Specialist – Endocrine
VA Boston Healthcare System
Adjunct Associate Professor of Pharmacy Practice
This case-based online activity will cover the treatment and management of patients with diabetes.
This educational activity is intended for primary care physicians, physician assistants, nurse practitioners, pharmacists, certified diabetes educators, and other HCPs who care for patients with diabetes.
Upon completion of the program, attendees should be able to:
- Evaluate the physiological role of GLP-1 and associated implications for the treatment of patients with diabetes.
- Review recommendations from current diabetes guidelines regarding the use of GLP-1 receptor agonists.
- Determine the advantages and disadvantages of individual GLP-1 receptor agonists in terms of efficacy, tolerability, dosing frequency, and administration requirements.
- Assess the effect of GLP-1 receptor agonists on glycemic and extra-glycemic outcomes.
- Discuss strategies for reducing adverse effects in patients receiving GLP-1 receptor agonists.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with diabetes. Credits: 1.0 ANCC Contact Hours
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTERESTS
Dhiren Patel, PharmD, CDE, BC-ADM, BCACP, is on the speakers’ bureau for AstraZeneca, Boehringer-Ingelheim, Merck & Co., Novo Nordisk, and Valeritas. Dr. Patel is a consultant for AstraZeneca, Becton & Dickinson, Boehringer-Ingelheim, Eli Lilly, Merck & Co., Novo Nordisk, and Sanofi.
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Ana Maria Albino, Program Manager for Med Learning Group, has nothing to disclose.
Diana Tommasi, Scientific and Medical Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: October 25, 2019
EXPIRATION DATE: October 25, 2020
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.